Phase 2 N=90 Trabectedin for Recurrent Grade II/III Meningioma
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Adult Grade I Meningioma · Adult Grade II Meningioma · Adult Grade III Meningioma
Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants
Phase 2 N=34 Monthly SOM230C for Recurrent or Progressive Meningioma
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Phase 2 N=50 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Acoustic Schwannoma · Adult Anaplastic Meningioma · Adult Ependymoma
Primary: Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months — 93; 85; 51; 73 percentage of patients
Phase 1 N=17 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
Phase 2 N=50 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Phase 2 N=21 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Glioblastoma · Gliosarcoma
Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants
Phase 2 N=25 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=25 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Glioblastoma · Astrocytoma · Oligodendroglioma
Primary: Progression-free Survival at 6-months — 17.3 percentage of participants
Phase 2 N=178 Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Brain and Central Nervous System Tumors
Primary: Progression-free Survival Rate at 3 Years — 92.2; 93.7; 58.8 percentage of participants
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=58 Dose-Intense Temozolomide in Recurrent Glioblastoma
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression Free Survival — 11 percentage of evaluable participants
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 2 N=31 Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
Phase 2 N=59 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=10 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Brain and Central Nervous System Tumors
Primary: Number of Patients Surviving Without Disease Progression After 6 Months — 0 participants